"Takeda Partners with Innovent Biologics to Enhance Oncology Pipeline with $1.2 Billion Deal"

"Baker McKenzie has facilitated a global strategic partnership between Takeda and Innovent Biologics, enhancing Takeda's oncology pipeline with investigational treatments for solid tumors. The agreement grants Takeda rights to two late-stage oncology assets, IBI363 and IBI343, outside Greater China, along with an exclusive option for an early-stage program, IBI3001. Takeda will lead the global co-development and commercialization efforts and plans to establish US manufacturing for these medicines. The deal includes a $1.2 billion upfront payment to Innovent, along with additional milestones and royalties."

Baker McKenzie represented Takeda in its global strategic partnership with Innovent Biologics. The transaction involves Takeda acquiring rights to two late-stage oncology assets, IBI363 and IBI343, outside of Greater China, along with an exclusive option to license an early-stage program, IBI3001. The agreement includes a USD 1.2 billion upfront payment to Innovent, with additional milestones and royalties, and Takeda will lead global co-development and commercialization efforts for these investigational medicines. The core Baker McKenzie team involved in this transaction includes Randy Sunberg (Partner, New York), Devin Muntz (Associate, Chicago), Anat Polyachenko (Associate, New York), and Julia Rossié (Associate, Munich) focusing on the licensing, option, and collaboration agreement; Christina Lee (Partner, Hong Kong) and Brian Wong (Partner, Hong Kong) handling the share issuance agreement; and Creighton Macy (Partner, Washington, DC) and Daniel Duk-ki Moon (Associate, Washington, DC) addressing HSR/antitrust matters.

"Takeda Partners with Innovent Biologics to Enhance Oncology Pipeline with $1.2 Billion Deal"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads